Medicare Compliance & Reimbursement
Reimbursement Rates For Popular Meds Under Fire
Payments for widely used pharmaceuticals could thin out if the HHS Office of Inspector General gets its way.
In a trio of reports released Feb. 2 by the OIG on the pricing of Lupron, ipratropium bromide and albuterol, the agency once again ups the ante on its already longstanding concern over skyrocketing pharmaceutical costs. It wants the Centers for Medicare & Medicaid Services to set "appropriate" payment rates for the drugs after 2004.
In 2002, the OIG says Medicare paid $677 million for the cancer drug Lupron - 8 percent of all drug reimbursements for that year. According to OIG data, Medicare could have saved $40 million if carriers in all jurisdictions had implemented a less costly alternative policy. One dose of a cheaper clinical equivalent, Zoladex, costs $446.49 - 27 percent less than the $611 for Lupron, the agency says in "Medicare Reimburse-ment for Lupron" (OEI-03-03-00250).
Medicare also pays more for albuterol and ipratropium bromide than other payors, the OIG says. If Medicare had reimbursed at the Medicaid federal upper limit amount in 2002 for albuterol, the program would have saved $263 million; for ipratropium bromide, savings would have amounted to another $386 million.
In "Update: Excessive Reimbursement for Ipratropium Bromide" (OEI-03-03-00520) and "Update: Excessive Reimbursement for Albuterol" (OEI-03-03-00510), the OIG argues that while pharmacies and other suppliers continue to enjoy falling prices on these drugs, the Medicare payment rate remains unchanged.
CMS agreed in part, but said its role in overseeing local medical review policies stopped short of influencing the "application of guidelines in any specific circumstance."
To see the reports, go to http://oig.hhs.gov/w-new.html.
Lesson Learned: Suppliers may see Medicare reimbursement rates of popular drugs fall next year if the OIG and CMS come to terms on pricing discrepancies.
Medicare Compliance & Reimbursement
- Medicare Advantage:
MedAdv Plans Lower Premiums, Enhance Benefits
Flush with federal funding, plans are making their products more attractive.
Less than a month after [...] - CMS Administration:
$1 Billion Not Enough To Implement New Law?
Responsible for revamping Medicare in two years, CMS is swamped.
Saying that their agency is swamped, [...] - Medicare Reform Law:
Momentum Builds To Reopen Medicare Law
Democrats want cheaper drugs, Republicans want cheaper Medicare.
Two Senators who voted for the Medicare bill, [...] - DME:
New Coalition Opposes Wheelchair Policy Changes
CMS tries to sneak in drastic changes through backdoor policy-making.
The durable medical equipment industry is [...] - Home Care:
Home Care Cuts On The Horizon
Increased Medicare bill cost estimate puts HHAs at risk.
Just when home health agencies are taking [...] - Regulation:
Got A Beef With CMS? Make Yourself Heard
It's easier than ever to give your 2 cents' worth on CMS' proposals.
Health care providers [...] - Politics:
GOP-Connected Firm Big Player On Medicare Ads
Are the new TV spots public service announcements or Bush reelection
Alexandria VA-based National Media Inc. [...] - Labs:
OIG Eyes State Lab Payment Policies
Audit could affect lab payments.
The HHS Office of Inspector General says the state of Massachusetts [...] - Pharmaceuticals:
Reimbursement Rates For Popular Meds Under Fire
OIG report claims Medicare is paying higher rates, losing millions.
Payments for widely used pharmaceuticals could [...] - Program Memo Roundup:
The interest rate for Medicare overpayments and underpayments will remain steady at 12 percent, the [...] - Bill Watch:
Bill introduced in the House: HR 3711. A bill to amend the Medicare Prescription Drug, [...]
